<DOC>
	<DOCNO>NCT01301755</DOCNO>
	<brief_summary>Invasive aspergillosis serious often fatal infection patient neutropenic undergone solid organ stem cell transplantation . However , early diagnosis invasive aspergillosis challenge . Reiss Lehmann first describe value serum Galactomanna ( GM ) diagnosis invasive pulmonary aspergillosis 1979 . The availability Platelia Aspergillus , sandwich ELISA approve FDA 2003 manage patient risk invasive aspergillosis early detection GM antigen . In several study far specificity serum galactomannan assay great 85 % ; however , variable sensitivity 29~100 % noted year . In addition , low value false-negative result see often nonneutropenic solid organ transplantation patient oppose severely granulocytopenic patient .There several factor might explain reported difference performance antigen detection , include biological factor epidemiological factor . In recent year , specimens body fluid increasingly use detection Aspergillus galactomannan antigen , include urine , bronchoalveolar lavage ( BAL ) fluid , cerebrospinal fluid even tissue specimen . However , sensitivity specificity GM detection various specimen still considerably variation . Ultrasound-guided transthoracic aspirate safe useful method collect specimen accurate bacteriologic diagnosis lung abscess obstructive pneumonitis10 . We also report study diagnosis pulmonary Cryptococosis ultrasound guide percutaneous aspiration . We plan perform prospective single-center study investigate role GM target organ ( lung tissue/fluid ) use ultrasound-guided fine needle aspirate early diagnosis invasive aspergillosis compare serum galactomannan .</brief_summary>
	<brief_title>Diagnosis Invasive Pulmonary Aspergillosis Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate Ultrasound-guided Fine Needle Aspiration</brief_title>
	<detailed_description>Invasive aspergillosis serious often fatal infection patient neutropenic undergone solid organ stem cell transplantation . However , early diagnosis invasive aspergillosis challenge . Reiss Lehmann first describe value serum Galactomanna ( GM ) diagnosis invasive pulmonary aspergillosis 1979 . Galactomannan water-soluble , polysaccharide cell wall component release Aspergillus fungal growth inhalation Aspergillus conidium lung . The availability Platelia Aspergillus , sandwich ELISA approve FDA 2003 manage patient risk invasive aspergillosis early detection GM antigen . In several study far specificity serum galactomannan assay great 85 % ; however , variable sensitivity 29~100 % noted year . In addition , low value false-negative result see often nonneutropenic solid organ transplantation patient oppose severely granulocytopenic patient .There several factor might explain reported difference performance antigen detection , include biological factor ( non-neutropenic patient , prior exposure antifungal agent , encapsulation abscess prevent GM leakage circulation , renal clearance , …etc . ) epidemiological factor ( patient population , cut-off value , prevalence infection…etc ) . In recent year , specimens body fluid increasingly use detection Aspergillus galactomannan antigen , include urine , bronchoalveolar lavage ( BAL ) fluid , cerebrospinal fluid even tissue specimen . However , sensitivity specificity GM detection various specimen still considerably variation . Ultrasound-guided transthoracic aspirate safe useful method collect specimen accurate bacteriologic diagnosis lung abscess obstructive pneumonitis10 . We also report study diagnosis pulmonary Cryptococosis ultrasound guide percutaneous aspiration . We plan perform prospective single-center study investigate role GM target organ ( lung tissue/fluid ) use ultrasound-guided fine needle aspirate early diagnosis invasive aspergillosis compare serum galactomannan .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<criteria>Eligible patient follow host factor : A hematologic malignancy , unless already treat antifungal presume proven IA Cancer receive chemotherapy within last 3 month admission Solid organ transplant recipient Prolong steroid use Recipient immunosuppressive treatment ( tacrolimus , cyclosporine , methotrexate , cyclophosphamide , sirolimus ) Child C cirrhosis HIV Febrile neutropenia Combined least two three follow feature : Fever ( &gt; 37.5。C ) refractory least 3 day appropriate antibiotic Fever relapse period defervescence least 48 hour still receive antibiotic Clinical sign and/or symptom suggestive invasive mycosis : pleuritic chest pain physical finding pleural rub , one follow symptom low respiratory tract infection ( new sputum secretion , dypsnea , hemoptysis ) Development new pulmonary infiltrates chest Xray HRCT Patients ca n't cooperative Have bleed tendency coagulopathy ( PLT &lt; 100K ) Pulmonary lesion could identify chest ultrasonography Patients informed consent procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>